CASE REPORT

Phenotypic overlap between pyruvate dehydrogenase complex deficiency and FOXG1 syndrome

Yuichi Akaba1 | Satoru Takahashi1 | Ryo Takeguchi1 | Ryosuke Tanaka1
Shin Nabatame2 | Hirotomo Saitsu3 | Naomichi Matsumoto4

1Department of Pediatrics, Asahikawa Medical University, Asahikawa, Japan
2Department of Pediatrics, Graduate School of Medicine, Osaka University, Osaka, Japan
3Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan
4Department of Human Genetics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

Correspondence
Yuichi Akaba, Department of Pediatrics, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan.
Email: akaba5p@asahikawa-med.ac.jp

Funding information
This work was supported in part by Japan Agency for Medical Research and Development (AMED) grants under the numbers JP20ek0109486, JP20ek0109301, JP20ek0109348, and JP20kk0205012 (to NM.), and Japan Society for the Promotion of Science (JSPS) KAKENHI JP17H01539 (to NM.).

Abstract
Pyruvate dehydrogenase complex (PDHC) deficiency is a mitochondrial disorder. We report two cases of PDHC deficiency with clinical symptoms and brain imaging findings reminiscent of FOXG1 syndrome, suggesting a phenotypic overlap of these disorders.

KEYWORDS
FOXG1 syndrome, MRI, PDHC deficiency, phenotype

1 | INTRODUCTION

Developmental encephalopathy (DE) is associated with developmental impairment, intellectual disability, and other neurological disorders such as epilepsy and movement disorders.1 DE has developmental consequences arising directly from the effect of genetic variants. The clinical features of patients with DE overlap with those of many neurodevelopmental disorders, and one disorder is difficult to distinguish from the others.

FOXG1 syndrome is one of the DEs, caused by a loss-of-function variant of FOXG1, that encodes a brain-specific transcriptional factor critical for forebrain development.2,3 Patients with FOXG1 syndrome show microcephaly, hyperkinetic movement disorder, severe psychomotor delay without regression, and characteristic brain imaging findings.2,4 Because hyperkinetic movement disorders commonly develop by 1 year of age, they are proposed as a diagnostic marker for FOXG1 syndrome.5

Pyruvate dehydrogenase complex (PDHC) deficiency is a mitochondrial disorder associated with lactic acidosis and various neurological symptoms. PDHC catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, a critical step in energy production.6

The clinical spectrum of PDHC deficiency ranges from episodic ataxia to severe fatal neonatal lactic acidosis, but involuntary movements are rare.7

Here, we report two cases of PDHC deficiency with clinical symptoms and brain imaging findings reminiscent of FOXG1 syndrome. They exhibited hyperkinetic involuntary movements and hand stereotypies, which are unusual for PDHC deficiency.7 This study demonstrates phenotypic overlap between PDHC deficiency and FOXG1 syndrome.
2 | CASE PRESENTATION

2.1 | Patient 1

This 31-year-old female patient was born to nonconsanguineous, healthy Japanese parents at 40 weeks of gestation after an uneventful pregnancy. Her birthweight and length were 2650 g (-1.1 SD) and 44.2 cm (-2.8 SD), respectively. Her occipitofrontal circumference (OFC) was 32 cm (-1.1 SD). She had no significant family medical history. Because of floppiness and inability to suck, she was fed through a nasogastric tube from the first day of life. At the age of 3 months, psychomotor delay, hypotonia, and strabismus were noted, and myoclonic seizures from the age of 11 months. The seizures were eventually controlled with phenytoin and phenobarbital. Developmental milestones were severely delayed; she acquired head control and turned over at 3 years and was never able to walk unaided and never acquired speech sounds. She displayed hand stereotypies with hand-to-mouth movements. Her OFC was 43.5 cm (-6.6 SD) at 8 years, indicating that microcephaly had become more evident with time. Magnetic resonance imaging (MRI) scans of the brain showed ventricular dilatation and hypoplasia of the frontal lobe and the corpus callosum (Figure 1A, B). Based on the clinical and brain MRI features, FOXG1 syndrome was initially suspected. However, genetic testing identified a disease-associated variant in PDHA1 but not in FOXG1. Metabolic investigations revealed increased levels of lactate (25.1 mg/dL) and pyruvate (1.93 mg/dL) in blood, leading to a definite diagnosis of PDHC deficiency. Lactate and pyruvate accumulation were reduced to 12.9 and 1.06 mg/dL, respectively, by administration of thiamine at a dose of 150 mg a day; however, her neurological condition did not improve.

2.2 | Patient 2

This female patient, aged 8 years, was born to nonconsanguineous, healthy Japanese parents at 41 weeks of gestation after an uneventful pregnancy. Her birthweight and OFC were 3156 g (0.1 SD) and 32.0 cm (-1.2 SD), respectively. She had no significant family medical history. During the neonatal period, she showed hypotonia, sleep disturbance, and inconsolable crying. The developmental milestones were severely delayed with no regression; she acquired head control at 6 months, turned over at 15 months, and sat up at 2 years. Because of feeding problems due to swallowing difficulties, she was fed via a nasogastric tube from 1 year and 9 months. Her head growth was postnatally decelerated and microcephaly became evident (OFCs of 40.2, 41.0, and 43.0 cm at 7 months, 1 year, and 2 years, respectively, all below -2 SD). At the age of 3 years, she remained incapable of standing up, acquiring speech.

FIGURE 1 (A-D) Images obtained when patient 1 (A and B) and patient 2 (C and D) were 29 and 3 years old, respectively. T1- and T2-weighted images of patients with PDHC deficiency show asymmetrical ventriculomegaly with subependymal cysts (A, arrows), ventricular septation (C, arrow), and hypoplasia of the corpus callosum (B and D)
sounds, and purposeful hand skills. She displayed prominent hyperkinetic movement disorders with hand stereotypies. Brain MRI scans showed microcephaly with hypoplasia of the frontal lobe and the corpus callosum (Figure 1C,D). She showed clinical features and brain MRI findings that were reminiscent of FOXG1 syndrome; however, she had increased lactate and pyruvate levels in blood (lactate 18.2 mg/dL, pyruvate 2.5 mg/dL) and cerebrospinal fluid (CSF) (lactate 32.6 mg/dL, pyruvate 3.3 mg/dL), although the lactate/pyruvate molar ratio was normal. Genetic testing revealed a disease-associated variant of PDHA1, leading to a diagnosis of PDHC deficiency. She was enrolled in a clinical trial of pyruvate therapy for mitochondrial diseases, which was effective in promoting motor development, but not the cognitive impairment. She was able to walk a few steps at 7 years of age, but remained unable to speak any meaningful words.

2.3 Identification of PDHA1 variants

Blood samples were collected from the patients and their parents after obtaining written informed consent from the parents. This study was approved by the Committee for Ethical Issues at Asahikawa Medical University. We performed whole exome sequencing in patient 1 as previously described and direct sequencing of PDHA1 in patient 2 and, in both, identified a same frameshift variant in PDHA1, NM_000284.3:c.934_940del, p.(Ser312Valfs*12) (Figure 2). Testing of the patients’ parents confirmed that the PDHA1 variant emerged de novo.

3 DISCUSSION

We identified a disease-associated variant in the X-linked PDHA1 in two female patients who were clinically suspected to have FOXG1 syndrome. Both had the same heterozygous deletion of a 7-bp repeat sequence in exon 10 of PDHA1. Gene deletions preferentially occur either within or in the vicinity of such tandem repeats. This mutation was also repeatedly reported in female patients with PDHC deficiency who exhibited variations in clinical severity, most probably due to different patterns of X-chromosome inactivation. Our patients exhibited similar clinical features, including microcephaly,
hypotonia, feeding difficulties, abnormal involuntary movements, stereotyped hand movements, and a profound delay in psychomotor development. Brain MRI scans revealed cerebral atrophy, ventriculomegaly, and hypoplasia of the corpus callosum. These features have been reported in patients with FOXG1 syndrome, suggesting a phenotypic overlap between PDHC deficiency and FOXG1 syndrome (Table 1).

Although patients with PDHC deficiency shared clinical features with FOXG1 syndrome, specific brain MRI findings may distinguish PDHC deficiency from FOXG1 syndrome. Corpus callosum hypogenesis was observed in both diseases. However, the corpus callosum in FOXG1 syndrome was affected mostly the anterior parts, whereas in PDHC deficiency, the posterior body and splenium were preferentially affected. Moreover, patients with PDHC deficiency had dilated ventricles with ventricular septations and/or subependymal cysts (Figure 1), probably due to a destructive process secondary to a metabolic defect, which were absent in FOXG1 syndrome. Subependymal cysts were also described in other metabolic disorders that cause primary lactic acidosis. Intraventricular septations probably reflect the evolution of subependymal cysts. Thus, none of the MRI findings described here is unique to PDHC deficiency. The detection of these MRI findings should prompt further investigation, including metabolic analysis and genetic testing for PDHA1 variants.

Most importantly, PDHC deficiency is commonly associated with lactic acidosis. Specific structural brain abnormalities, with the characteristic clinical features, may allow distinction of PDHC deficiency from FOXG1 syndrome if the lactate and pyruvate levels are elevated in the blood and/or CSF. The correct diagnosis will lead to effective treatment. The therapeutic options that may be beneficial in some patients with PDHC deficiency include ketogenic diet, supplementation with thiamine, and dichloroacetate. Therefore, this study further reinforces the necessity of measuring the lactate and pyruvate levels in blood and/or CSF even in the cases of clinically suspected FOXG1 syndrome.

**ACKNOWLEDGMENTS**
We thank all the patients and their family members. The permission was obtained from the patient's parents for presentation.

**CONFLICT OF INTEREST**
None declared.

**AUTHOR CONTRIBUTIONS**
YA: contributed to collecting all the clinical data and writing of the draft manuscript. ST: contributed to literature review and revision of the manuscript. RT, RT, SN, HS, and NM critically reviewed the manuscript. All Authors approved the contents of the submitted manuscript.

**ETHICAL APPROVAL**
Institutional approval was obtained. No identifiable patient information was presented in this report.

**DATA AVAILABILITY STATEMENT**
Not applicable.

**ORCID**
Yuichi Akaba  
https://orcid.org/0000-0001-6226-3648

**REFERENCES**
1. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:512-521.
2. Ariani F, Hayek G, Rondinella D, et al. FOXG1 is responsible for the congenital variant of Rett syndrome. *Am J Hum Genet*. 2008;83:89-93.

3. Wong LC, Singh S, Wang HP, Hsu CJ, Hu SC, Lee WT. FOXG1-related syndrome: from clinical to molecular genetics and pathogenic mechanisms. *Int J Mol Sci*. 2019;20:e4176.

4. Bahi-Buisson N, Nectoux J, Girard B, et al. Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant. *Neurogenetics*. 2010;11:241-249.

5. Caporali C, Signorini S, Giorgis VD, Pichiecchio A, Zuffardi O, Orcesi S. Early-onset movement disorder as diagnostic marker in genetic syndromes: three cases of FOXG1-related syndrome. *Eur Paediatr Neurol*. 2018;22:336-339.

6. Brown GK. Pyruvate dehydrogenase E1α deficiency. *J Inherit Metab Dis*. 1992;15:625-633.

7. Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. *Mol Genet Metab*. 2012;105:34-43.

8. Koga Y, Povalko N, Katayama K, et al. Beneficial effect of pyruvate therapy on Leigh syndrome due to a novel mutation in PDH E1α gene. *Brain Dev*. 2012;34:87-91.

9. Sakamoto M, Kouhei D, Haniffa M, et al. A novel ITPA variant causes epileptic encephalopathy with multiple-organ dysfunction. *J Hum Genet*. 2020;65:751-757.

10. Krawczak M, Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. *Hum Genet*. 1991;86:425-441.

11. Lissens W, De Meirleir L, Seneca S, et al. Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. *Hum Mutat*. 2000;15:209-219.

12. Kortüm F, Das S, Flindt M, et al. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. *J Med Genet*. 2011;48:396-406.

13. Takahashi S, Matsumoto N, Okayama A, et al. FOXG1 mutations in Japanese patients with the congenital variant of Rett syndrome. *Clin Genet*. 2012;82:569-573.

14. Kumakura A, Takahashi S, Okajima K, Hata D. A haploinsufficiency of FOXG1 identified in a boy with congenital variant of Rett syndrome. *Brain Dev*. 2014;36:725-729.

15. Vegas N, Cavallin M, Maillard C, et al. Delineating FOXG1 syndrome: from congenital microcephaly to hyperkinetic encephalopathy. *Neuro Genet*. 2018;4:e281.

16. Ah Mew N, Loewenstein JB, Kadom N, et al. MRI features of 4 female patients with pyruvate dehydrogenase E1 alpha deficiency. *Pediatr Neurol*. 2011;45:57-59.

17. Dey R, Mine M, Desguerre I, et al. A new case of pyruvate dehydrogenase deficiency due to a novel mutation in the PDX1 Gene. *Ann Neurol*. 2003;53:273-277.

18. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. *Pediatrics*. 2006;117:1519-1531.

How to cite this article: Akaba Y, Takahashi S, Takeguchi R, et al. Phenotypic overlap between pyruvate dehydrogenase complex deficiency and FOXG1 syndrome. *Clin Case Rep*. 2021;9:1711–1715. [https://doi.org/10.1002/ccr3.3883](https://doi.org/10.1002/ccr3.3883)